Dolutegravir (Tivicay)
The Latest
This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Tsepamo Study Provides Critical Update on Neural Tube Defects and Dolutegravir
A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.
DAWNING Study Casts New Light on the Details of Resistance
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
This Week in HIV Research: Pregnancy Findings That Aren't About Dolutegravir
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
IAS 2019: What to Expect in HIV Science
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
This Week in HIV Research: The Racism of Perceived Risk
June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.